KESTRA MEDICAL TECHNOLOGIES, LTD. financial statements
Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data KESTRA MEDICAL TECHNOLOGIES, LTD. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
FY2026
Revenue
27.8
59.8
95.1
Cost of revenue
27.5
35.6
46.3
Gross profit
0.36
24.2
48.9
Research and development
15.5
15.7
19.5
Selling, general and administrative
69.9
115
164
Operating expenses
85.4
131
184
Operating income
-85.1
-106
-135
Interest expense
6.23
7.73
7.55
Interest income
3.2
8.35
Other non-operating income
-2.8
-2.77
2.62
Pre-tax income
-94.1
-114
-131
Income tax
0.02
0.14
0.29
Net income
-94.1
-114
-132
EBITDA
-73.5
-98.4
-126
EPS, basic
-5.07
-5.13
-2.43
EPS, diluted
-5.07
-5.13
-2.43
Shares, basic (weighted)
19.9
24.6
54.2
Shares, diluted (weighted)
19.9
24.6
54.2
Balance sheet
FY2025
FY2025
FY2026
Cash and equivalents
8.25
238
99.7
Short-term investments
96.7
Receivables
2
8.08
14.5
Other current assets
0.42
1.69
2.98
Total current assets
14.9
255
222
Property, plant and equipment
26.1
34.8
59.1
Lease right-of-use assets
2.29
2.08
3.36
Long-term investments
65.8
Other non-current assets
0.61
1.15
5.79
Total assets
45.9
296
358
Accounts payable
23.9
24
27.3
Accrued liabilities
9.08
13.8
23
Total current liabilities
33
38
50.4
Long-term debt
42.5
41.1
42.6
Lease liabilities
2.63
3.03
4.11
Other non-current liabilities
0.08
0.14
0.31
Total liabilities
78.2
90.3
98.8
Total debt
42.5
41.1
42.6
Paid-in capital
177
674
853
Retained earnings
-406
-520
-652
Other comprehensive income
-0.22
Total equity
-209
205
260
Total liabilities and equity
45.9
296
358
Shares outstanding
0.11
51.3
58.4
Cash flow statement
FY2025
FY2025
FY2026
Net income
-94.1
-114
-132
Depreciation and amortization
11.6
7.97
8.71
Stock-based compensation
1.49
24.3
33.6
Deferred income tax
0.01
0.06
0.17
Change in receivables
-2.5
-8.78
-9.06
Change in payables
7.34
2.84
4.3
Cash from operations
-72.2
-77.6
-81.7
Capital expenditures
-12.2
-22.9
-34.9
Purchases of investments
-163
Cash from investing
-12.2
-23.3
-203
Debt issued
45
Debt repaid
-39.1
Stock issued
216
149
Cash from financing
77.7
330
147
Net change in cash
-6.74
229
-138
Free cash flow
-84.5
-101
-117
Interest paid
3.63
4.85
5.65
Income taxes paid
-0.03
0.08
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to July 31, 2026; growth uses fiscal years. Valuation uses the share price of $27.14 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
53.9%
Gross profit / revenue.
Operating margin
-134.5%
Operating income / revenue.
EBITDA margin
-125.7%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-140.1%
Pre-tax income / revenue.
Net margin
-140.4%
Net income / revenue.
FCF margin
-115.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-82.2%
Cash from operations / revenue.
Return on assets (ROA)
-43.1%
Net income / average total assets.
R&D / revenue
20.9%
Research and development expense / revenue.
SG&A / revenue
167.5%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
36.2%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
32.9%
Capital expenditures / revenue.
D&A / revenue
8.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
59.0%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
101.8%
Gross profit vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
21.2%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
120.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.69x
Current assets / current liabilities.
Quick ratio
4.44x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.12x
(Cash + short-term investments) / current liabilities.
Debt / assets
20.9%
Total debt / total assets.
Liabilities / assets
36.0%
Total liabilities / total assets.
Net debt
-$126.4M
Total debt - cash - short-term investments. Negative means more cash than debt.
Interest coverage
-19.0x
Operating income / interest expense.
Working capital
$178.0M
Current assets - current liabilities.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.31x
Revenue / average total assets.
Fixed asset turnover
1.68x
Revenue / average property, plant and equipment.
Receivables turnover
6.93x
Revenue / average receivables.
Days sales outstanding
53 days
365 x average receivables / revenue.
Days payables
193 days
365 x average accounts payable / cost of revenue.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$2.56
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Market cap + total debt - cash - short-term investments.
P/S
14.9x
Market cap / revenue.
EV/Sales
13.7x
Enterprise value / revenue.
FCF yield
-7.7%
Free cash flow / market cap.
Earnings yield
-9.4%
Net income / market cap (the inverse of P/E).
What was KESTRA MEDICAL TECHNOLOGIES, LTD.'s revenue in fiscal 2026?
KESTRA MEDICAL TECHNOLOGIES, LTD. reported revenue of $95.1M for fiscal 2026, 59% higher than the year before.
Was KESTRA MEDICAL TECHNOLOGIES, LTD. profitable in fiscal 2026?
No. It reported a net loss of $131.6M.
How much free cash flow did KESTRA MEDICAL TECHNOLOGIES, LTD. generate in fiscal 2026?
Cash from operations of $81.7M minus capital expenditures of $34.9M left free cash flow of -$116.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.